Table 3 Factors associated with pre-treatment drug resistance mutations among enrolled participants, 2008–2010
Variable | Mutation | No mutation | OR | 95 % CI |
|---|---|---|---|---|
Sex | ||||
Female | 68 | 947 | 1.22 | 0.76–1.96 |
Male | 25 | 426 | ||
Previous exposure to ARVs | ||||
Yes | 11 | 65 | 2.58 | 1.30–5.12* |
No | 65 | 991 | ||
WHO clinical stage | ||||
3 or 4 | 65 | 887 | 1.14 | 0.69–1.88 |
1 or 2 | 22 | 343 | ||
CD4 count (cells/mm 3 ) | ||||
<350 | 43 | 635 | 1.02 | 0.6–1.55 |
≥350 | 50 | 752 | ||
Viral load (copies/ml) | ||||
≥1000 | 86 | 1288 | 0.47 | 0.14–1.60 |
<1000 | 3 | 21 | ||